Finland · Delayed Price · Currency is EUR Orion Oyj Company Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.
The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex, and Dexmedetomidine products for human use.
It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other companies.
It has discovery service and commercial license agreement with Invenra to develop bispecific antibody cancer therapeutics; and collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics.
Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
| Country | Finland |
| Founded | 1917 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 3,880 |
| CEO | Liisa Hurme |
Contact Details
Address: Orionintie 1A Espo, 02200 Finland | |
| Phone | 358 10 4261 |
| Website | orionpharma.com |
Stock Details
| Ticker Symbol | ORNAV |
| Exchange | Nasdaq Helsinki |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FI0009014369 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Liisa Hurme Ph.D. | President, Chief Executive Officer and Chairman of Executive Management Board |
| Rene Lindell M.Sc., Ph.D. | Chief Financial Officer and Member of Group Executive Management Board |
| Satu Ahomäki M.Sc., M.Sc. (Econ.) | Senior Vice President of Generics and Consumer Health Business Division and Member of the Exe. Mgmt. Board |
| Prof. Outi Vaarala M.D., Ph.D. | Senior Vice President of Innovative Medicines, Sr. VP of Research & Development and Member of the Exe. Mgmt. Board |
| Juhani Kankaanpaa | Senior Vice President of Global Operations and Member of Executive Management Board |
| Niclas Lindstedt EMBA, M.Sc. | Senior Vice President of Animal Health Business Division and Member of the Exe. Mgmt. Board |
| Hao Pan M.Sc. | Senior Vice President of the Branded Products Business Division and Member of the Exe. Mgmt. Board |
| Julia Irene Macharey | Senior Vice President of People and Culture and Member of Management Board |
| Mikko Kemppainen | General Counsel, Secretary to the Board and Member of Executive Management Board |
| Tuukka Hirvonen M.Sc.(Soc.) | Investor Relations and Financial Communications Officer |